febrile neutropenia
Conditions
Interventions
Exprimental group:imipenem-cilastatin combined with Linezolid
Control group:imipenem-cilastatin monotherapy
Sponsors
Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years, both female and male; 2. ANC of 5×normal values) or renal insufficiency (defined as a creatinine clearance of <30 mL/min).
Exclusion criteria
Exclusion criteria: 1. patients who were pregnant or lactating; 2. Known allergy to drugs being prescribed; 3. Patients that can't guarantee complete the plan and follow up; 4. Intravenous antibiotics are being used when entering the group; 5. Indications for addition of antibiotics active against gram-positive organisms: 1) Hemodynamic instability or other evidence of severe sepsis; 2) Clinically suspected serious catheter-related infection (eg, chills or rigors with infusion through catheter and cellulitis around the catheter entry/exit site); 3) Skin or soft-tissue infection at any site; 4) Pneumonia documented radiographically.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| defervescence time;clinical effective rate;bacterial clearance rate; | — |
Countries
China
Contacts
Public ContactWang Chun
Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine
Outcome results
None listed